UNSPSC 51292923: Lofepramine hydrochloride

This classification denotes an antidepressant agent with the molecular formula C26H27ClN2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z24K96F991, chemically known as 5h-dibenz(b,f)azepine, 5-(3-((p-chlorobenzoylmethyl)-n-methylamino)propyl)-, hydrochloride but more generally known as lofepramine hydrochloride, which bears US NIH Compound Identifier 33611. European Medicines Agency schedules Lofepramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02965MIG.

UNSPSC 51292923 Lofepramine hydrochloride is a Commodity code that addresses pharmaceutical products, though recent state and local procurement activity under this code shows minimal relevant sourcing. The single recent opportunity identified—Seminole County, Florida's IFB 60459723LAS—is tagged to this code but actually solicits naloxone and safe drug deactivation systems, products outside the scope of lofepramine hydrochloride, a tricyclic antidepressant medication. The mismatch suggests either a classification error in the county's tagging or a data inconsistency that reduces the reliability of this code for tracking genuine lofepramine procurement.

Seminole County, Florida posted the opportunity on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, through a two-year contract with a one-year renewal option. The IFB required electronic bid submission with an original deadline of July 26, 2023 (a date that predates the posting, indicating a data entry error in the source). Bidders must provide unit costs, comply with drug-free workplace and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance. The procurement is potentially FEMA-funded and includes a three-month probationary termination clause. The code shows no other recent state or local opportunities and does not support a meaningful characterization of issuing-body mix, geographic concentration, or market activity for lofepramine hydrochloride itself.